Vnitr Lek 2019, 65(11):704-710 | DOI: 10.36290/vnl.2019.122

Sekundární prevence ischemické choroby srdeční a chorob periferních tepen kombinací antiagregační a antikoagulační léčby. Odborné stanovisko České kardiologické společnosti, České internistické společnosti ČLS J.E. Purkyně a České angiologické společnosti ČLS J.E. Purkyně k výsledkům studie COMPASS

Petr Widimský1,*, Debora Karetová4, Richard Češka2, Miloš Táborský5, Hana Rosolová3, Jean-Claude Lubanda4, Aleš Linhart4
1 Kardiocentrum 3. LF UK a FN Královské Vinohrady, Praha
2 Centrum preventivní kardiologie III. interní kliniky 1. LF UK a VFN v Praze
3 Centrum preventivní kardiologie II. interní kliniky LF UK a FN Plzeň
4 II. interní klinika kardiologie a angiologie 1. LF UK a VFN v Praze
5 I. interní klinika - kardiologická LF UP a FN Olomouc

Received: April 24, 2019; Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský P, Karetová D, Češka R, Táborský M, Rosolová H, Lubanda J, Linhart A. Sekundární prevence ischemické choroby srdeční a chorob periferních tepen kombinací antiagregační a antikoagulační léčby. Odborné stanovisko České kardiologické společnosti, České internistické společnosti ČLS J.E. Purkyně a České angiologické společnosti ČLS J.E. Purkyně k výsledkům studie COMPASS. Vnitr Lek. 2019;65(11):704-710. doi: 10.36290/vnl.2019.122.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bruthans J, Cífková R, Lánská V et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol 2014; 21(7): 829-839. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487312469476>. Go to original source... Go to PubMed...
    2. Piepoli MF, Hoes AW, Agewall S et al. [ESC Scientific Document Group]. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>. Go to original source... Go to PubMed...
    3. Kotseva K, Wood D, De Bacquer D et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factors and therapeutic managements of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23(6): 636-648. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487315569401>. Go to original source... Go to PubMed...
    4. Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39(2): 119-177. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx393>. Go to original source... Go to PubMed...
    5. Catapano AL, Graham I, De Backer G et al. et al. [ESC Scientific Document Group]. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39): 2999-3058. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw272>. Go to original source... Go to PubMed...
    6. Williams B, Mancia I, Spiering W et al. ESC Scientific Document Group. 2018 ESC/EHS Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-3104. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehy339>. Go to original source... Go to PubMed...
    7. Bhatt DL, Steg PG, Ohman EM et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 2006; 295(2): 180-189. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.295.2.180>. Go to original source... Go to PubMed...
    8. [CAPRIE Steering Committee]. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329-1339. Go to original source... Go to PubMed...
    9. Hiatt WR, Fowkes FG, Heizer G et al. [EUCLID Trial Steering Committee and Investigators]. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med 2017; 376(1): 32-40. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611688>. Go to original source... Go to PubMed...
    10. Aboyans V, Ricco JB, Bartelink ME et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration With the European Society for Vascular Surgery (ESVS): Document Covering Atherosclerotic Disease of Extracranial Carotid and Vertebral, Mesenteric, Renal, Upper and Lower Extremity Arteries. Eur Heart J 2018; 39(9): 763-816. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx095>. Go to original source... Go to PubMed...
    11. Mega JL, Braunwald E, Wiviott SD et al. [ATLAS ACS 2-TIMI 51 Investigators]. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366(1): 9-19. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1112277>. Go to original source... Go to PubMed...
    12. Bosch J, Eikelboom JW, Connolly SJ et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol 2017; 33(8): 1027-1035. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cjca.2017.06.001>. Go to original source... Go to PubMed...
    13. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, Aspirin or Both After Myocardial Infarction. N Engl J Med 2002; 347(13): 969-974. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa020496>. Go to original source... Go to PubMed...
    14. Eikelboom JW, Connolly SJ, Bosch J et al. [COMPASS Investigators]. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14): 1319-1330. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1709118>. Go to original source... Go to PubMed...
    15. Connolly SJ, Eikelboom JW, Bosch J et al. [COMPASS investigators]. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391(10117): 205-218. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(17)32458-3>. Go to original source... Go to PubMed...
    16. Lamy A, Eikelboom J, Sheth T et l. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. J Am Coll Cardiol 2019; 73(2): 121-130. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2018.10.048>. Go to original source... Go to PubMed...
    17. Anand SS, Bosch J, Eikelboom JW et al. [COMPASS Investigators]. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391(10117): 219-229. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(17)32409-1>. Go to original source... Go to PubMed...
    18. [Study (CARS) Investigators]. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction. Lancet 1997; 350(9075): 389-396. Go to original source...
    19. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351(9098): 233-241. Go to original source...
    20. Herlitz J, Holm J, Peterson M et al. [LoWASA study group]. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction. Eur Heart J 2004; 25(3): 232-239. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ehj.2003.10.026>. Go to original source... Go to PubMed...
    21. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347(13): 969-974. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa020496>. Go to original source... Go to PubMed...
    22. Andreotti F, Testa L, Biondi-Zoccai GG et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27(5): 519-526. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehi485>. Go to original source... Go to PubMed...
    23. Alexander JH, Lopes RD, James S et al. [APPRAISE-2 Investigators]. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. N Engl J Med 2011; 365(8): 699-708. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1105819>. Go to original source... Go to PubMed...
    24. Oldgren J, Budaj A, Granger CB et al. [RE-DEEM Investigators]. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32(22): 2781-2789. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr113>. Go to original source... Go to PubMed...
    25. Marc P, Bonaca MD, Deepak L et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med 2015; 372(19): 1791-1800. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1500857>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.